07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Complement 3 (C3); complement component 1 q subcomponent (C1q); complement component 1 q subcomponent A chain (C1QA)

Neurology INDICATION: Alzheimer's disease (AD) Studies in mice suggest inhibiting C3, the C3-activator C1q , or the C1q subunit C1QA could help treat AD. Hippocampal and cortical levels of C1q were higher in two transgenic...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity; metabolic syndrome Complement component 1q subcomponent (C1Q); complement component 1q subcomponent A chain (C1QA) Mouse studies suggest inhibiting C1Q signaling could help prevent...
07:00 , Mar 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma Complement component 1 q subcomponent A chain (C1QA); endothelin 2 (EDN2) Mouse studies suggest that antagonists of C1QA and...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

Prostate Cancer Survival Precision Profile cancer data

In a study of 62 castration-resistant prostate cancer patients, the Prostate Cancer Survival Precision Profile test was 96% accurate in predicting low-risk CRPC patients (those who lived >2.2 years) and 93% accurate in predicting high-risk...
08:00 , Jan 8, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Complement component 1q subcomponent A chain (C1QA) Studies in mice suggest that blocking specific components of...